Abstract: Chronic rhinosinusitis (CRS) is a chronic inflammatory disease of the nasal and paranasal cavities. About 20% of chronic rhinosinusitis is represented by rhinosinusitis with nasal polyps (CRSwNP), which in most cases is caused by a type 2 inflammation, with an eosinophilic inflammation.
Monoclonal antibodies are a targeted therapy that allows you to control the disease by limiting or abolishing the use of systemic steroids.
In this scientific work, the authors tested the efficacy of mepolizumab and dupilumab in patients with nasosinusal polyposis with a 12-month follow-up.
Keywords: Chronic Rhinosinositis, nasal polyps, monoclonal antibodies, mepolizumab, dupilimab.
Title: Monoclonal Antibodies in Chronic Rhinosinusitis with nasal polips (CRSwNP): our 12 months experience
Author: F.Asprea, D. Bruzzese, D. Costanzo, G.Lucchesi, G.Micali
International Journal of Healthcare Sciences
ISSN 2348-5728 (Online)
Vol. 10, Issue 2, October 2022 - March 2023
Page No: 181-186
Research Publish Journals
Website: www.researchpublish.com
Published Date: 17-January-2023
